Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Early Treatment of Psoriasis: Quality of Life, Comorbidities, and Disease Modification
Description
The speaker argues that psoriasis should often be treated early, not just based on body surface area, but when quality of life is meaningfully impaired, behavior changes, or comorbidities such as psoriatic arthritis are suspected. He emphasizes that clinicians should think in terms of preventing poor outcomes rather than waiting for disease to worsen, and that patient fears, physician hesitancy, and treatment burden contribute to undertreatment. He highlights evidence that early intervention may improve quality of life, reduce cardiovascular and mortality risk, and potentially prevent or delay psoriatic arthritis damage. He also presents data suggesting earlier disease responds better to treatment, may recur more slowly after stopping therapy, and could be linked to fewer inflammatory memory cells, implying that early treatment might even modify disease course. Overall, he concludes that early psoriasis treatment can be life-changing and should be pursued more proactively.
Conclusions
- Psoriasis should be treated earlier when quality of life is significantly impaired, even if body surface area is not very high, because waiting can prolong suffering and functional decline.
- The presentation argues that clinicians should reframe the issue from “should we treat early?” to “can we justify delay?”, with treatment decisions driven by preventing poor outcomes.
- Delayed treatment is common because of physician-patient disconnect, fear of systemic therapy, access barriers, and prescribing burden, not because early treatment lacks rationale.
- Newer oral and systemic options may serve as a practical bridge for patients who are reluctant to start injections or biologics, making earlier intervention more feasible.
- Early recognition of scalp, nail, and musculoskeletal symptoms is important because these features can signal higher risk for psoriatic arthritis and other comorbidities.
- Dermatologists are positioned to detect psoriatic arthritis early, and earlier identification may help prevent irreversible joint damage and disability.
- Psoriasis appears to be linked to cardiovascular risk and overall mortality, and observational data suggest that biologics or methotrexate may reduce all-cause and cardiovascular death.
- The risk of not treating moderate-to-severe psoriasis may be greater than the perceived risk of treatment, so undertreatment may represent a missed opportunity for better long-term outcomes.
- Treating psoriasis early may make the disease easier to control later, with better response durability and longer treatment-free remission in some studies.
- Early treatment may alter disease biology by reducing tissue-resident memory T cells and accelerating normalization of inflammatory gene expression in skin.
- Overall, the talk concludes that early psoriasis treatment can improve quality of life immediately and may also reduce comorbidity burden and potentially modify the course of skin disease over time.
- Gold, L. et al. 2025 American Academy of Dermatology Innovation Academy in Chicago.
- Song J. et al., EADV 2025, D1T01.2B.
- McGonagle et al. Dermatology 2009.
- Langley RG, et al. J Am Acad Dermatol 2021 Jan;84(1):60-69. doi: 10.1016/
- Eyerich K., et al. BMJ Open 2021;11:e049822. doi:10.1136/bmjopen-2021-049822.#10.1136/bmjopen-2021-049822
- Iversen L, et al. ESDR 2022; P365.
- Langley RG et al. JAAD, 2026 (in press) Online February 03, 2026.
- Langley RG etal. JAAD, 2026 (in press) Online February 03, 2026.